53
Participants
Start Date
June 28, 2016
Primary Completion Date
February 14, 2022
Study Completion Date
March 31, 2024
LBH589
"STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.~STRATUM 2: Non-progressed DIPG or H3K27M+ Thalamic DMG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria."
Memorial Sloan Kettering Cancer Center, New York
Children's Hospital of Pittsburgh, Pittsburgh
Children's National Medical Center, Washington D.C.
National Cancer Institute, Bethesda
St. Jude Children's Research Hospital, Memphis
Cincinnati Children's Hospital Medical Center, Cincinnati
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Baylor College of Medicine, Houston
Children's Hospital Los Angeles, Los Angeles
Stanford University and Lucile Packard Children's Hospital, Palo Alto
National Cancer Institute (NCI)
NIH
Pediatric Brain Tumor Consortium
NETWORK